Kanchi Karpooram (538896)

Score breakdown: P/E: 1/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Price nearly equals book value (P/B 1.00, book value ₹489.63 vs price ₹491.85), providing asset backing if the balance sheet is sound.
• ROCE of 9.44% is positive, indicating some operational capital efficiency despite weak ROE.
• Latest quarter sales of ₹34 crore show the business is still operational.
• Trading at the top of its 52-week range suggests current market interest and momentum.

Concerns

• Latest quarter net profit is ₹0 crore, and profit growth is -37.50%, signaling weak earnings power.
• ROE of only 2.50% means the asset base is generating very low returns for shareholders.
• Piotroski F-Score of 3/9 points to poor fundamental health and possible financial deterioration.
• P/E of 27.39 is expensive for a commodity chemical business with declining sales; dividend yield is negligible at 0.30%.

AI Analysis

At first glance, Kanchi Karpooram looks like a classic asset play. The share price of ₹491.85 sits just above book value of ₹489.63, so I am effectively buying ₹1 of net assets for ₹1. But as Graham warned, price is what you pay, value is what you get. The value of an asset is its ability to generate earnings. Here, that ability is poor: return on equity is just 2.50%, return on capital employed is 9.44%, and the latest quarter delivered exactly ₹0 crore of net profit on ₹34 crore of sales. This is a commodity chemical business. I see no economic moat, no pricing power, and no distinctive brand. Sales have fallen 4.53% and profit has dropped 37.50% over the period reported. The company earns only a tiny dividend yield of 0.30%, so shareholders are not being paid to wait. The Piotroski F-score of only 3 out of 9 reinforces my concerns: this is not a financially improving business. At 27.39 times trailing earnings, the market is paying a rich multiple for shrinking earnings. With no debt/equity data and no promoter holding disclosed, I cannot even complete a proper balance-sheet check. The only bullish case is the balance sheet itself: a price-to-book of 1.00 gives some asset support, and the stock is at its 52-week high, suggesting some investor enthusiasm. But buying a commodity chemical near book value is not automatically value investing. If the assets cannot earn a decent return, book value can erode. I would need a much lower price, or clear evidence of a turnaround, before acting. This is an interesting balance-sheet stock to study, but not a business I would confidently label as a value bargain.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer